Colorectal Cancer,Gastrointestinal Cancer Nivolumab Plus Low-Dose Ipilimumab as First-Line Treatment for mCRC Jun 01, 2023
Colorectal Cancer,Gastrointestinal Cancer Evaluating the Efficacy of GDC-6036 in Advanced Solid Tumors with KRAS G12C Mutation Jun 01, 2023
Colorectal Cancer,Gastrointestinal Cancer Botensilimab Plus Balstilimab in Heavily Pretreated MSS CRC: Phase 1A/1B Results Jun 01, 2023
Colorectal Cancer,Gastrointestinal Cancer High-Dose Vitamin C + FOLFOX ± Bevacizumab v FOLFOX ± Bevacizumab in mCRC Evaluated May 24, 2023
Colorectal Cancer,Gastrointestinal Cancer Fruquintinib Effectiveness in Third-line mCC Compared to Other Targeted Kinase Inhibitors May 22, 2023
Colorectal Cancer,Gastrointestinal Cancer Enhancing Immunotherapy Efficacy in Metastatic Colorectal or NSCLC with Durvalumab and Tremelimumab: Phase II Study Apr 17, 2023
Colorectal Cancer,Gastrointestinal Cancer Phase 3 XELAVIRI Trial: Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC Apr 17, 2023
Colorectal Cancer,Gastrointestinal Cancer Maya Phase 2 Study: Nivolumab Plus Ipilimumab and Temozolomide in Microsatellite Stable, MGMT Silenced mCRC Apr 17, 2023